{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T14:38:05Z","timestamp":1771943885071,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB854"],"award-info":[{"award-number":["SFB854"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00277-019-03819-3","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T14:37:03Z","timestamp":1573223823000},"page":"2729-2737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5254-9885","authenticated-orcid":false,"given":"Vanja","family":"Zeremski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Jentsch-Ullrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Kahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Mohren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1892-5098","authenticated-orcid":false,"given":"Enrico","family":"Schalk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"key":"3819_CR1","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/ajh.24819","volume":"92","author":"C Saygin","year":"2017","unstructured":"Saygin C, Jia X, Hill B, Dean R, Pohlman B, Smith MR, Jagadeesh D (2017) Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma. Am J Hematol 92:989\u2013996. \nhttps:\/\/doi.org\/10.1002\/ajh.24819","journal-title":"Am J Hematol"},{"key":"3819_CR2","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2217\/fon-2018-0788","volume":"15","author":"VA Morrison","year":"2019","unstructured":"Morrison VA, Shou Y, Bell JA, Hamilton L, Ogbonnaya A, Raju A, Hennenfent K, Eaddy M, Galaznik A (2019) Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA. Future Oncol 15:1021\u20131034. \nhttps:\/\/doi.org\/10.2217\/fon-2018-0788","journal-title":"Future Oncol"},{"key":"3819_CR3","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","unstructured":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329:987\u2013994","journal-title":"N Engl J Med"},{"key":"3819_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.critrevonc.2005.04.008","volume":"55","author":"ML Janssen-Heijnen","year":"2005","unstructured":"Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW (2005) Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 55:231\u2013240. \nhttps:\/\/doi.org\/10.1016\/j.critrevonc.2005.04.008","journal-title":"Crit Rev Oncol Hematol"},{"key":"3819_CR5","doi-asserted-by":"publisher","first-page":"5103","DOI":"10.1182\/blood-2010-07-259333","volume":"116","author":"M Pfreundschuh","year":"2010","unstructured":"Pfreundschuh M (2010) How I treat elderly patients with diffuse large B-cell lymphoma. Blood 116:5103\u20135110. \nhttps:\/\/doi.org\/10.1182\/blood-2010-07-259333","journal-title":"Blood"},{"key":"3819_CR6","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1002\/cncr.30173","volume":"122","author":"D Chihara","year":"2014","unstructured":"Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ (2014) Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer 122:3145\u20133151. \nhttps:\/\/doi.org\/10.1002\/cncr.30173","journal-title":"Cancer"},{"key":"3819_CR7","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/annonc\/mdx413","volume":"29","author":"C Buske","year":"2018","unstructured":"Buske C, Hutchings M, Ladetto M, Goede V, Mey U, Soubeyran P, Spina M, Stauder R, Trneny M, Wedding U, Fields P, ESMO Lymphoma Consensus Conference Panel Members (2018) ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Ann Oncol 29:544\u2013562. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdx413","journal-title":"Ann Oncol"},{"key":"3819_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11864-018-0565-6","volume":"19","author":"A Kumar","year":"2018","unstructured":"Kumar A, Fraz MA, Usman M, Malik SU, Ijaz A, Durer C, Durer S, Tariq MJ, Khan AY, Qureshi A, Faridi W, Nasar A, Anwer F (2018) Treating diffuse large B cell lymphoma in the very old or frail patients. Curr Treat Options in Oncol 19:50. \nhttps:\/\/doi.org\/10.1007\/s11864-018-0565-6","journal-title":"Curr Treat Options in Oncol"},{"key":"3819_CR9","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3109\/10428194.2013.810737","volume":"55","author":"K Boslooper","year":"2014","unstructured":"Boslooper K, Kibbelaar R, Storm H, Veeger NJ, Hovenga S, Woolthuis G, van Rees B, de Graaf E, van Roon E, Kluin-Nelemans HC, Joosten P, Hoogendoorn M (2014) Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. Leuk Lymphoma 55:526\u2013532. \nhttps:\/\/doi.org\/10.3109\/10428194.2013.810737","journal-title":"Leuk Lymphoma"},{"key":"3819_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.clml.2016.06.003","volume":"16","author":"JM Byun","year":"2016","unstructured":"Byun JM, Lee JO, Kang B, Kim JW, Kim SH, Kim JW, Kim YJ, Lee KW, Bang SM, Lee JS (2016) Diffuse large B-cell lymphoma in the elderly: real world outcomes of immunochemotherapy in Asian population. Clin Lymphoma Myeloma Leuk 16:503\u2013510. \nhttps:\/\/doi.org\/10.1016\/j.clml.2016.06.003","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3819_CR11","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, Solal-Celigny P, Offner F, Walewski J, Raposo J, Jack A, Smith P (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417\u20131423. \nhttps:\/\/doi.org\/10.1182\/blood-2004-08-3175","journal-title":"Blood"},{"key":"3819_CR12","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","volume":"12","author":"F Peyrade","year":"2011","unstructured":"Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, Andr\u00e9 M, Fournier M, Gaulard P, Tilly H, Groupe d\u2019Etude des Lymphomes de l\u2019Adulte (GELA) investigators (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 12:460\u2013468. \nhttps:\/\/doi.org\/10.1016\/S1470-2045(11)70069-9","journal-title":"Lancet Oncol"},{"key":"3819_CR13","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","volume":"32","author":"PA Fields","year":"2014","unstructured":"Fields PA, Townsend W, Webb A, Counsell N, Pocock C, Smith P, Jack A, El-Mehidi N, Johnson PW, Radford J, Linch DC, Cunnningham D (2014) De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial. J Clin Oncol 32:282\u2013287. \nhttps:\/\/doi.org\/10.1200\/JCO.2013.49.7586","journal-title":"J Clin Oncol"},{"key":"3819_CR14","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1016\/S2352-3026(18)30054-1","volume":"5","author":"QD Shen","year":"2018","unstructured":"Shen QD, Zhu HY, Wang L, Fan L, Liang JH, Cao L, Wu W, Xia Y, Li JY, Xu W (2018) Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial. Lancet Haematol 5:e261\u2013e269. \nhttps:\/\/doi.org\/10.1016\/S2352-3026(18)30054-1","journal-title":"Lancet Haematol"},{"key":"3819_CR15","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, Josten KM, D\u00fcrk H, Rost A, Neise M, von Gr\u00fcnhagen U, Chow KU, Hansmann ML, Hoelzer D, Mitrou PS (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol 23:3383\u20133389. \nhttps:\/\/doi.org\/10.1200\/JCO.2005.08.100","journal-title":"J Clin Oncol"},{"key":"3819_CR16","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM (2014) Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123:2944\u20132952. \nhttps:\/\/doi.org\/10.1182\/blood-2013-11-531327","journal-title":"Blood"},{"key":"3819_CR17","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/annonc\/mdq671","volume":"22","author":"E Weidmann","year":"2011","unstructured":"Weidmann E, Neumann A, Fauth F, Atmaca A, Al-Batran SE, Pauligk C, J\u00e4ger E (2011) Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol 22:1839\u20131844. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdq671","journal-title":"Ann Oncol"},{"key":"3819_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/bjh.14232","volume":"175","author":"SI Park","year":"2016","unstructured":"Park SI, Grover NS, Olajide O, Asch AS, Wall JG, Richards KL, Sobol AL, Deal AM, Ivanova A, Foster MC, Muss HB, Shea TC (2016) A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma. Br J Haematol 175:281\u2013289. \nhttps:\/\/doi.org\/10.1111\/bjh.14232","journal-title":"Br J Haematol"},{"key":"3819_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3324\/haematol.2017.186569","volume":"103","author":"S Storti","year":"2018","unstructured":"Storti S, Spina M, Pesce EA, Salvi F, Merli M, Ruffini A, Cabras G, Chiappella A, Angelucci E, Fabbri A, Liberati AM, Tani M, Musuraca G, Molinari A, Petrilli MP, Palladino C, Ciancia R, Ferrario A, Gasbarrino C, Monaco F, Fraticelli V, De Vellis A, Merli F, Luminari S (2018) Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi. Haematologica 103:1345\u20131350. \nhttps:\/\/doi.org\/10.3324\/haematol.2017.186569","journal-title":"Haematologica"},{"key":"3819_CR20","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1182\/blood.V122.21.4371.4371","volume":"122","author":"FJ Hammersen","year":"2013","unstructured":"Hammersen FJ, Sommer M, G\u00f6ssel C, Teichgr\u00e4ber U, Hahnfeld S, Scholl S, Fricke HJ, Wedding U, Ekkehard E, Iver P, Merz H, Hochhaus A, La Ros\u00e9ee P (2013) Safety and efficacy of bendamustine in patients with aggressive non-Hodgkin lymphomas (NHL). Blood 122:4371","journal-title":"Blood"},{"key":"3819_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ejh.13069","volume":"101","author":"CL Cheng","year":"2018","unstructured":"Cheng CL, Liu JH, Chou SC, Yao M, Tang JL, Tien HF (2018) Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B-cell lymphoma. Eur J Haematol 101:28\u201337. \nhttps:\/\/doi.org\/10.1111\/ejh.13069","journal-title":"Eur J Haematol"},{"issue":"suppl 4","key":"3819_CR22","first-page":"44","volume":"41","author":"FJ Hammersen","year":"2018","unstructured":"Hammersen FJ, R\u00fcthrich MM, Wedding U, Sommer M, Hochhaus A, La Rosee P (2018) Comparison of R-miniCHOP with R-Bendamustine (R-B) in diffuse large B-cell Lymphoma (DLBCL) in elderly and comorbid patients. Oncol Res Treat 41(suppl 4):44 abstract P173","journal-title":"Oncol Res Treat"},{"key":"3819_CR23","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245\u20131251","journal-title":"J Clin Epidemiol"},{"key":"3819_CR24","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191\u20132194. \nhttps:\/\/doi.org\/10.1001\/jama.2013.281053","journal-title":"JAMA"},{"key":"3819_CR25","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-L\u00f3pez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17:1244\u20131253. \nhttps:\/\/doi.org\/10.1200\/JCO.1999.17.4.1244","journal-title":"J Clin Oncol"},{"key":"3819_CR26","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.hoc.2007.06.011","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586. \nhttps:\/\/doi.org\/10.1016\/j.hoc.2007.06.011","journal-title":"J Clin Oncol"},{"key":"3819_CR27","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1634\/theoncologist.2014-0113","volume":"19","author":"PA Hamlin","year":"2014","unstructured":"Hamlin PA, Satram-Hoang S, Reyes C, Hoang KQ, Guduru SR, Skettino S (2014) Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis. Oncologist 19:1249\u20131257. \nhttps:\/\/doi.org\/10.1634\/theoncologist.2014-0113","journal-title":"Oncologist"},{"key":"3819_CR28","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ejim.2014.05.001","volume":"25","author":"S Diem","year":"2014","unstructured":"Diem S, Ess S, Cerny T, Fr\u00fch M, Hitz F (2014) Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis. Eur J Intern Med 25:577\u2013582. \nhttps:\/\/doi.org\/10.1016\/j.ejim.2014.05.001","journal-title":"Eur J Intern Med"},{"key":"3819_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3109\/10428194.2014.903589","volume":"56","author":"YY Tien","year":"2015","unstructured":"Tien YY, Link BK, Brooks JM, Wright K, Chrischilles E (2015) Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile. Leuk Lymphoma 56:65\u201371. \nhttps:\/\/doi.org\/10.3109\/10428194.2014.903589","journal-title":"Leuk Lymphoma"},{"key":"3819_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejca.2018.05.006","volume":"99","author":"MB Juul","year":"2018","unstructured":"Juul MB, Jensen PH, Engberg H, Wehberg S, Dessau-Arp A, Haziri D, Kristensen HB, Baech J, Schurmann L, Clausen MR, Valentin R, Knudsen LM, Munksgaard L, El-Galaly TC, Frederiksen H, Larsen TS (2018) Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study. Eur J Cancer 99:86\u201396. \nhttps:\/\/doi.org\/10.1016\/j.ejca.2018.05.006","journal-title":"Eur J Cancer"},{"key":"3819_CR31","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Gr\u00fcnhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, D\u00fcrk H, Ballo H, Stauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W, Study group indolent Lymphomas (StiL) (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, bendamustine, bendamustine, phase 3 non-inferiority trial. Lancet 381:1203\u20131210. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(12)61763-2","journal-title":"Lancet"},{"key":"3819_CR32","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.ctrv.2013.01.007","volume":"39","author":"C Bellera","year":"2013","unstructured":"Bellera C, Praud D, Petit-Mon\u00e9ger A, McKelvie-Sebileau P, Soubeyran P, Mathoulin-P\u00e9lissier S (2013) Barriers to inclusion of older adults in randomised controlled clinical trials on non-Hodgkin\u2019s lymphoma: a systematic review. Cancer Treat Rev 39:812\u2013817. \nhttps:\/\/doi.org\/10.1016\/j.ctrv.2013.01.007","journal-title":"Cancer Treat Rev"},{"key":"3819_CR33","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1093\/annonc\/mdt592","volume":"25","author":"ME Hamaker","year":"2014","unstructured":"Hamaker ME, Stauder R, van Munster BC (2014) On-going clinical trials for elderly patients with a hematological malignancy: are we addressing the right end points? Ann Oncol 25:675\u2013681. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdt592","journal-title":"Ann Oncol"},{"key":"3819_CR34","unstructured":"ClinicalTrials.gov\n\n (2019) \nhttps:\/\/clinicaltrials.gov\n\n (accessed at 11\/06\/2019)"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03819-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03819-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03819-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:10:30Z","timestamp":1604707830000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03819-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3819"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03819-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]},"assertion":[{"value":"12 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}